115 related articles for article (PubMed ID: 18689277)
1. Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia.
Essa EA; El Halim SM; Abo-Elenin A; El Bendary A; Abdou SH; Farag W
Egypt J Immunol; 2007; 14(1):11-20. PubMed ID: 18689277
[TBL] [Abstract][Full Text] [Related]
2. Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms.
Horie R; Gattei V; Ito K; Imajo-Ohmi S; Tange T; Miyauchi J; Pinto A; Degan M; De Iuliis A; Tassan Mazzocco F; Rossi FM; Higashihara M; Watanabe T
Am J Pathol; 1999 Dec; 155(6):2029-41. PubMed ID: 10595933
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD30 mRNA, CD30L mRNA and a variant form of CD30 mRNA in restimulated peripheral blood mononuclear cells (PBMC) of patients with helminthic infections resembling a Th2 disease.
Kilwinski J; Berger T; Mpalaskas J; Reuter S; Flick W; Kern P
Clin Exp Immunol; 1999 Jan; 115(1):114-9. PubMed ID: 9933429
[TBL] [Abstract][Full Text] [Related]
4. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
5. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice.
Sun X; Yamada H; Shibata K; Muta H; Tani K; Podack ER; Yoshikai Y
J Immunol; 2010 Aug; 185(4):2222-30. PubMed ID: 20639486
[TBL] [Abstract][Full Text] [Related]
6. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin.
Gattei V; Degan M; Gloghini A; De Iuliis A; Improta S; Rossi FM; Aldinucci D; Perin V; Serraino D; Babare R; Zagonel V; Gruss HJ; Carbone A; Pinto A
Blood; 1997 Mar; 89(6):2048-59. PubMed ID: 9058727
[TBL] [Abstract][Full Text] [Related]
7. CD30 ligand is expressed on resting normal and malignant human B lymphocytes.
Younes A; Consoli U; Zhao S; Snell V; Thomas E; Gruss HJ; Cabanillas F; Andreeff M
Br J Haematol; 1996 Jun; 93(3):569-71. PubMed ID: 8652374
[TBL] [Abstract][Full Text] [Related]
8. CD30 ligand is a new therapeutic target for central nervous system autoimmunity.
Shinoda K; Sun X; Oyamada A; Yamada H; Muta H; Podack ER; Kira J; Yoshikai Y
J Autoimmun; 2015 Feb; 57():14-23. PubMed ID: 25533628
[TBL] [Abstract][Full Text] [Related]
9. In rheumatoid arthritis soluble CD30 ligand is present at high levels and induces apoptosis of CD30(+)T cells.
Tinazzi E; Barbieri A; Rigo A; Patuzzo G; Beri R; Gerli R; Argentino G; Puccetti A; Lunardi C
Immunol Lett; 2014 Oct; 161(2):236-40. PubMed ID: 24447865
[TBL] [Abstract][Full Text] [Related]
10. CD30 ligand in lymphoma patients with CD30+ tumors.
Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases.
Oflazoglu E; Grewal IS; Gerber H
Adv Exp Med Biol; 2009; 647():174-85. PubMed ID: 19760074
[TBL] [Abstract][Full Text] [Related]
12. Deciphering CD30 ligand biology and its role in humoral immunity.
Kennedy MK; Willis CR; Armitage RJ
Immunology; 2006 Jun; 118(2):143-52. PubMed ID: 16771849
[TBL] [Abstract][Full Text] [Related]
13. Characterization of CD30/CD30L(+) Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis.
Barbieri A; Dolcino M; Tinazzi E; Rigo A; Argentino G; Patuzzo G; Ottria A; Beri R; Puccetti A; Lunardi C
J Immunol Res; 2015; 2015():729654. PubMed ID: 26090498
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells.
Rossi FM; Degan M; Mazzocco FT; Di Francia R; Aldinucci D; Poletto D; Vellenga E; Pinto A; Gattei V
Br J Haematol; 2002 Apr; 117(1):59-69. PubMed ID: 11918534
[TBL] [Abstract][Full Text] [Related]
15. CD30 ligand (CD30L)-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cells proliferation.
Gattei V; Degan M; Rossi FM; de Iuliis A; Mazzocco FT; Serraino D; Zagonel V; Aldinucci D; Pinto A
Leuk Lymphoma; 1999 Sep; 35(1-2):21-35. PubMed ID: 10512160
[TBL] [Abstract][Full Text] [Related]
16. CD30 in systemic mastocytosis.
van Anrooij B; Kluin PM; Oude Elberink JN; Kluin-Nelemans JC
Immunol Allergy Clin North Am; 2014 May; 34(2):341-55. PubMed ID: 24745678
[TBL] [Abstract][Full Text] [Related]
17. [Expression of PRAME gene in acute leukemia and its clinical significance].
Zhu YL; Liu J; Zhu P; DU JW; Zhang Y; Gu JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1144-9. PubMed ID: 18088454
[TBL] [Abstract][Full Text] [Related]
18. [The expression and clinical significance of early differentiation antigens in acute leukemia].
Zhou Y; Li Q; Meng HX; Wang YF; Yu Z; Qiu LG
Zhonghua Nei Ke Za Zhi; 2005 Jan; 44(1):46-9. PubMed ID: 15769398
[TBL] [Abstract][Full Text] [Related]
19. Reverse signaling via CD30 ligand.
Wiley SR; Goodwin RG; Smith CA
J Immunol; 1996 Oct; 157(8):3635-9. PubMed ID: 8871664
[TBL] [Abstract][Full Text] [Related]
20. The central role of CD30L/CD30 interactions in allergic rhinitis pathogenesis in mice.
Fuchiwaki T; Sun X; Fujimura K; Yamada H; Shibata K; Muta H; Podack ER; Kawauchi H; Yoshikai Y
Eur J Immunol; 2011 Oct; 41(10):2947-54. PubMed ID: 21739429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
